Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
48
Participants
Timeline
Start Date
November 8, 2017
Primary Completion Date
February 16, 2018
Study Completion Date
February 16, 2018
Conditions
Healthy Participants
Interventions
DRUG
Perampanel
IV infusion
DRUG
Perampanel
Oral tablet
Trial Locations (1)
92801
Anaheim Clinical Trials, Anaheim
All Listed Sponsors
lead
Eisai Inc.
INDUSTRY
NCT03376997 - Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects | Biotech Hunter | Biotech Hunter